Nab-paclitaxel in first-line treatment of advanced non–small-cell lung cancer

Article Type
Changed
Fri, 01/04/2019 - 11:07
Display Headline
Nab-paclitaxel in first-line treatment of advanced non–small-cell lung cancer

Nanoparticle albumin-bound (nab-) paclitaxel is a solvent-free paclitaxel formulation that has been designed to reduce adverse reactions associated with conventional solvent-based paclitaxel formulations and to improve paclitaxel tumor penetration by exploiting the physiologic transport properties of albumin. In a recently reported phase 3 trial that compared nab-paclitaxel and solvent-based paclitaxel injection in combination with carboplatin as first-line treatment of advanced non–small-cell lung cancer (NSCLC), nab-paclitaxel was associated with a significantly greater overall response rate (ORR), the primary end point, and a reduced risk of neuropathy.1 The findings in this international trial, combined with the demonstration of paclitaxel efficacy in this setting, supported the recent approval of nab-paclitaxel combined with carboplatin as first-line treatment of advanced NSCLC. Subset analyses in the trial suggested some potential response and survival advantages with nab-paclitaxel treatment.

*Click on the links to the left for PDFs of the full article and related Commentary.  

Article PDF
Author and Disclosure Information

Publications
Topics
Legacy Keywords
nab-paclitaxel, non-small-cell lung cancer, NSCLC,
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

Nanoparticle albumin-bound (nab-) paclitaxel is a solvent-free paclitaxel formulation that has been designed to reduce adverse reactions associated with conventional solvent-based paclitaxel formulations and to improve paclitaxel tumor penetration by exploiting the physiologic transport properties of albumin. In a recently reported phase 3 trial that compared nab-paclitaxel and solvent-based paclitaxel injection in combination with carboplatin as first-line treatment of advanced non–small-cell lung cancer (NSCLC), nab-paclitaxel was associated with a significantly greater overall response rate (ORR), the primary end point, and a reduced risk of neuropathy.1 The findings in this international trial, combined with the demonstration of paclitaxel efficacy in this setting, supported the recent approval of nab-paclitaxel combined with carboplatin as first-line treatment of advanced NSCLC. Subset analyses in the trial suggested some potential response and survival advantages with nab-paclitaxel treatment.

*Click on the links to the left for PDFs of the full article and related Commentary.  

Nanoparticle albumin-bound (nab-) paclitaxel is a solvent-free paclitaxel formulation that has been designed to reduce adverse reactions associated with conventional solvent-based paclitaxel formulations and to improve paclitaxel tumor penetration by exploiting the physiologic transport properties of albumin. In a recently reported phase 3 trial that compared nab-paclitaxel and solvent-based paclitaxel injection in combination with carboplatin as first-line treatment of advanced non–small-cell lung cancer (NSCLC), nab-paclitaxel was associated with a significantly greater overall response rate (ORR), the primary end point, and a reduced risk of neuropathy.1 The findings in this international trial, combined with the demonstration of paclitaxel efficacy in this setting, supported the recent approval of nab-paclitaxel combined with carboplatin as first-line treatment of advanced NSCLC. Subset analyses in the trial suggested some potential response and survival advantages with nab-paclitaxel treatment.

*Click on the links to the left for PDFs of the full article and related Commentary.  

Publications
Publications
Topics
Article Type
Display Headline
Nab-paclitaxel in first-line treatment of advanced non–small-cell lung cancer
Display Headline
Nab-paclitaxel in first-line treatment of advanced non–small-cell lung cancer
Legacy Keywords
nab-paclitaxel, non-small-cell lung cancer, NSCLC,
Legacy Keywords
nab-paclitaxel, non-small-cell lung cancer, NSCLC,
Article Source

PURLs Copyright

Inside the Article

Article PDF Media